Sign in
CompletedPhase 4

14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection

Key facts

Who runs it
National Cheng-Kung University Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
46 people enrolled
Started
22 Aug 2022
Ended
26 Jan 2024
Type of study
Interventional
Treatments tested
  • Bismuth-based susceptibility-guided treatment
Record updated
13 November 2024

Who can take part

Age
20 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • H. pylori-infected with treatment experience with at least one course of eradication failure
  • H. pylori-infected with treatment naïve but having multiple-drug resistant H. pylori (>= three antibiotics)
  • H. pylori infection confirmed by H. pylori culture

Who cannot take part

  • Previous allergic reactions to regimens, including amoxicillin, bismuth subcitrate, esomeprazole, metronidazole, rifabutin, and tetracycline,
  • Chronic kidney disease with estimated glomerular filtration rate < 60 ml/min/1.73 m2,
  • Dual-resistant H. pylori infection
  • Mono-resistant H. pylori infection
  • All susceptible H. pylori infection
  • Severe comorbidities,
  • Pregnant or breastfeeding women
  • Positive RUT but negative H. pylori culture
  • Negative RUT and negative H. pylori culture
  • Decline to participate

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if the 14-day susceptibility-guided bismuth quadruple therapy works to treat multiple drug resistant Helicobacter pylori (H. pylori) in adults. It will also learn about the adverse effects of bismuth quadruple therapy. The main questions it aims to answer are:

Read full original descriptionShow less

* Does 14-day susceptibility-guided bismuth quadruple therapy higher the eradication rate? * What medical problems do participants have when taking 14-day susceptibility-guided bismuth quadruple? Researchers will record 14-day susceptibility-guided bismuth quadruple to see if 14-day susceptibility-guided bismuth quadruple works to treat multiple drug resistant H. pylori.

Participants will:

* Take susceptibility-guided bismuth quadruple every day for 14 days * Visit the clinic once 4-6 weeks for checkups and tests * Keep a diary of their symptoms during taking susceptibility-guided bismuth quadruple

The group in the trial

  • Bismuth-based susceptibility-guided treatmentTreatment being tested

    Participants who have triple- or quadruple-drug resistant H. pylori infection are enrolled. Participants receive one of the four regimens based on susceptibility test.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Study of Adding Bismuth on Susceptibility-based Regimen Strategy to Enhance the Eradication Rate for Multi-resistant H. Pylori Infection
Record updated
13 November 2024